Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia by Immunomodulatory and Epigenetic Drugs by Fuchs, Ota
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Treatment of Myelodysplastic Syndrome and Acute
Myeloid Leukemia by Immunomodulatory and
Epigenetic Drugs
Ota Fuchs
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/52099
1. Introduction
Acute myeloid leukemia (AML) is associated with poor prognosis in elderly patients. More
effective, less toxic therapies for older patients with AML who are not eligible for standard
intensive induction therapy or have refractory or relapsed disease after chemotherapy are
urgently needed. Epigenetic approaches with hypomethylating agents and histone deacety‐
lase inhibitors and immunomodulatory drugs used in advance in the treatment of patients
with myelodysplastic syndrome (MDS) have been also studied in patients with AML [1-15].
MDS is a diverse goup of clonal hematopoietic stem cell disorders manifested by ineffective
production of blood cells with varying need for transfusions, risk of infection, and risk of
transformation to AML. Epigenetic changes, such as DNA methylation, histone acetylation,
and RNA interference alter gene expression impacting disease biology and play an impor‐
tant role in the pathogenesis of both, MDS and AML. Hypermethylation of CpG islands in
the promoters of key genes involved in cell cycle regulation, apoptosis, tumor suppressor
control and in response to chemotherapy and the consequent silencing of their expression is
well documented in MDS. Hypermethylated DNA sequences of key cellular machinery pro‐
vide an attractive potential therapeutic target for the treatment of MDS. DNA methylation
and histone modification not only regulate the expression of protein-encoding genes but al‐
so microRNAs (miRs), such as let-7a, miR-9, miR-34a, miR-124, miR-137, miR-148, miR-203
and miR-223 [16-22]. The only approved way to inhibit DNA methylation is to use clinically
available inhibitors of enzymes- DNA methyltransferases (DNMTs). Treatment with DNMT
inhibitors is a rational strategy with the aim to reinduce the expression of epigenetically si‐
lenced genes for tumor suppressors and other targeted genes, often connected with response
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to chemotherapy. It can induce a broad spektrum of apoptotic pathways. This strategy is
valid not only for MDS but for human cancer generally, including AML. 5-Aza-cytidine
(azacidine, Vidaza) and 5-aza-2´-deoxycytidine (5-azaCdR decitabine) have become the
standard in the treatment of patients with higher-risk MDS, in particular older individuals,
where intensive chemotherapy and allogeneic stem cell transplantation is not possible.
Azacitidine (Vidaza, Celgene Corporation, Summit, NJ, USA or Celgene Europe Ltd., Wins‐
dor, UK) was the first drug approved for the treatment of MDS in the United States and in
the European Union. Decitabine (Dacogen, Eisai Inc., Woodcliff Lake, NJ, USA under license
from Astex Pharmaceuticals, Inc., Dublin, CA, USA) received initial regulatory approval
from the US Food and Drug Administration (FDA) in May 2006 for the treatment of patients
with all MDS subtypes [23-25]. Since then, decitabine has also gained regulatory approval in
Russia, Malaysia, South Korea, the Philippines, Uruguay, Chile, Argentina, Peru, Colombia,
and Brazil, and is considered for approval in other countries. European Organisation for Re‐
search and Treatment of Cancer (EORTC) conducted study, which failed to reveal a signifi‐
cant improvement in overall survival, time to AML transformation and death, for low-dose
decitabine compared to the best supportive care [26-31].
About 80-90% of 5-aza-cytidine is incorporated into RNA which disrupts nucleic acid and
protein metabolism leading to apoptosis. The rest of 5-azacytidine (10-20%) inhibits DNA
synthesis through conversion to decitabine triphosphate and subsequent DNA incorpora‐
tion. Recently, precise mechanism of azacitidine action has been described. Azacitidine in‐
hibits ribonucleotide reductase subunit and causes perturbation of the pool of
deoxyribonucleotide triphosphates.
The median survival for azacitidine-treated patients with AML (75mg/m2/day for 7 days) in
a phase III randomized trial was 24.5 months, compared with 16 months for AML patients
receiving conventional care regimens [4]. Complete remisson rates were 18% for patients re‐
ceiving azacitidine, 15% for patients receiving low-dose cytarabine, and 55% for patients re‐
ceiving intensive induction therapy [4, 5]. Multicenter, phase II study of decitabine (20
mg/m2/day for 5 days) for the first-line treatment of older patients with AML found remis‐
sions in 25% of patients, with a median overall survival of 7.7 months and a 30-day mortali‐
ty rate of 7% [5]. Another study in older AML patients treated with a 10-day schedule of
decitabine showed that 47% of patients achieved complete remission without added toxicity
[32]. Despite these encouraging results, in a randomized phase III trial, decitabine produced
complete remission in 18% older patients with AML but without the significant improve‐
ment in overall survival in comparison with patients receiving supportive care or low-dose
cytarabine [25]. Several new studies show a little better results [33, 34]. New randomized
studies evaluating single-agent decitabine versus conventional treatment are warranted. A
low incidence of treatment-related toxicity has been reported for both these agents, azaciti‐
dine and decitabine, supports their use for older AML patients, mainly for those unable or
unwilling to receive standard intensive chemotherapy.
Decitabine maintains normal hematopoietic stem cell (HSC) self-renewal but induces terminal
differentiation in AML cells. AML cells express low levels of the key late differentiation factor
CEBPE (CCAAT/enhancer binding protein epsilon). CEBPE promoter CpGs are usually hypo‐
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methylated during granulocyte maturation but are significantly hypermethylated in AML
cells [35]. Decitabine-induced hypomethylation is greatest at these and other promoter CpGs
that are usually hypomethylated with myeloid maturation, accompanied by cellular differen‐
tiation of AML cells. In contrast, decitabine-treated normal HSC retained immature morphol‐
ogy. High expression of lineage-specifying factor and aberrant epigenetic repression of some
late differentiation factors distinguishes AML cells from normal HSCs and could explain the
contrasting differentiation and methylation responses to decitabine. Decitabine induced up-
regulation of several apoptosis-related genes, in particular of DAP-kinase 1  and BCL2L10.
BCL2L10 was hypermethylated in 45% of AML but not in healthy controls [36].
Another  inhibitors  of  DNMTs  (5,6-dihydro-5-azacytidine,  2´-deoxy-5,6-dihydro-5-azacyti‐
dine, a second-generation hypo-methylating agent SGI-110 /a dinucleotide of decitabine and
deoxyguanosine linked with a natural phosphodiester linkage/, zebularine, procaine, epigal‐
locatechin-3-gallate, and N-phthalyl-L-tryptophan) are in preclinical studies or in clinical tri‐
als [37, 38].
The second epigenetic target for which drugs are available is histone deacetylation. There
are several histone deacetylases (HDAC) inhibitors (romidepsin, vorinostat, belinostat, so‐
dium phenylbutyrate, valproic acid, entinostat, and mocetinostat) in preclinical studies or in
clinical trials [6, 10, 11]. Vorinostat and valproic acid received approval from the US FDA
and are available for clinical use in the USA.
Clinical studies with dual pharmacologic targeting of DNMT and HDAC enzymes (azaciti‐
dine and phenylbutyrate or decitabine plus vorinostat) reported overall response rate of
22% in MDS/AML patients and supported preclinical results where synergistic anticancer
activity was found [12, 39, 40].
Clinical benefit from the immunomodulatory agent lenalidomide (CC5013, Revlimid®) in
patients with lower-risk MDS associated with deletion of the long arm of chromosome 5
(del(5q)) led to its 2005 FDA approval for red blood cell transfusion-dependent anemia due
to low or intermediate-1 risk MDS associated with a chromosome 5q deletion with or with‐
out additional cytogenetic abnormalities. Lenalidomide functions through immunomodula‐
tory, anti-inflammatory, anti-angiogenic and direct neoplastic cells inhibitory mechanisms
[41-43]. The highly encouraging results with lenalidomide in del(5q) lower-risk MDS were
not repeated in del(5q) AML. The cause of this difference is in many cases deletion of anoth‐
er commonly deleted region 5q31 and not of the 5q32-33 including RPS14. However, there is
the clear activity of lenalidomide in a subset of patients with AML [8, 9]. Safety, efficacy and
biological predictors of response to sequential azacitidine and lenalidomide for elderly pa‐
tients with acute myeloid leukemia were also studied [14]. This therapy was well tolerated
with encouraging clinical and biological activity.
The regulation of gene expression by DNA methylation
DNA methylation is a covalent modification at position C5 of the cytidine ring in the context
of a CpG dinucleotide. This methylation is catalysed by a family of DNMTs including
DNMT1, DNMT3A and DNMT3B. DNMT1 is required for maintenance methylation during
DNA replication. DNMT3A and DNMT3B function in de novo methylation [44-47]. CpG rich
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regions called CpG islands are present in about half of human gene promoters. Methylation
of these CpG islands is associated with transcriptional silencing from the involved promot‐
ers. When the CpG islands are highly methylated, they bind specific proteins which recruit
transcriptional co-repressors such as histone deacetylases (HDACs). Epigenetic silencing is
also associated with histone H3 lysine 9 (H3K9) methylation. This modification is associated
with closed chromatin and results also in transcriptional suppression. Alterations in DNA
methylation are important in the pathogenesis of MDS [48]. Increasing evidence shows aber‐
rant hypermethylation of genes occurring in and potentially contributing to pathogenesis of
MDS. The tumor suppressor and cell cycle regulatory gene CDKN2B (cyclin-dependent kin‐
ase inhibitor 2B) is an example of hypermethylated gene in MDS resulting in silenced ex‐
pression of this cell cycle inhibitor p15INK4B (cyclin-dependent kinase 4 inhibitor B) and in
uncontrolled cell cycle progression and cellular proliferation. CDKN2B methylation is fre‐
quent in refractory anemia with excess blasts in transformation, therapy-related MDS, and
in chronic myelomonocytic leukemia [49-52]. Increased methylation of CDKN2B gene is con‐
nected with disease progression. Methylation level of CDKN2B gene might be used as a
marker of leukemic transformation in MDS [53].
Reversal of aberrant methylation by the treatment with hypomethylating agents leads to re-
expression of silenced tumor suppressor genes and some other genes, often connected with
response to chemotherapy (CDKN2B, cyclin-dependent kinase inhibitor 2A /CDKN2A/ cod‐
ing for p16INK4A, the cell-adhesion genes /cadherin-1 /CDH-1/, cadherin-13 /CDH-13/, and im‐
munoglobulin superfamily member 4 /IGSF4/, the pro-apoptotic death-associated protein
serine/threonine kinase gene /DAP-kinase/, the suppressor of cytokine signaling-1 /SOCS1/,
the reversion-induced LIM homeodomain containing gene /RIL/, a ligand-dependent sup‐
pressor deleted in colorectal cancer /DCC/, a growth regulatory and tumor suppressor gene
hypermethylated in cancer /HIC1/, dinucleosidetriphosphatase-fragile histidine triad gene /
FHIT/ involved in purine metabolism, calcitonin, arachidonate 12- lipoxygenase /ALOX12/
involved in the production and metabolism of fatty acid hydroperoxidases, glutathione S-
transferase Mu1 /GSTM1/, testes-specific serine protease 50 /TSP50/, O-6-methylguanine-
DNA methyltransferase /MGMT/, Krüppel like factor 11 /KLF11/, oligodendrocyte lineage
transcription factor 2 /OLIG2/, estrogen receptor alpha /ESR1/, progesterone receptors PGRA
and PGRB, RAS association domain family1A /RASSF1/, functioning in the control of micro‐
tubule polymerization and potentially in the maintenance of genomic stability, and BLU,
both tumor suppressors genes located at 3p21.3, retinoic acid receptor beta /RARB/, a nucle‐
ar transcription factor which mediates cellular signaling, cell growth and differentiation,
and neutrophic tyrosine kinase receptor, type 1 /NTRK1/), which is needed to transmit sig‐
nals for cell growth and survival [54-57].
In the recent years, the discovery of a series of mutations in patients with MDS has provided
insight into the pathogenesis of MDS. Among these alternations have been mutations in
genes, such as IDH1, IDH2, TET2, and DNMT3A, which affect DNA methylation [58-61].
These mutations are discussed in the special chapter.
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2. Types of histone methylation modification and their regulatory
mechanisms
Histone methylation is carried out by several histone methyltransferases that methylate ly‐
sine (HKMTs) or arginines (PRMTs) in histone tails [62-65]. The four core histones, H2A,
H2B, H3, and H4, make up the nucleosome, the main structural unit of chromatin. Some
specific histone tail modification, such as methylation of histone 3 lysine tail residue 4
(H3K4), are associated with activation of gene expression, while others, such as methylation
of histone 3 lysine 27 (H3K27), are associated with gene repression [66]. These marks are
normally carefully controlled by the interplay of sequence-specific DNA binding transcrip‐
tion factors and transcriptional cofactors, many of which are histone-modifying enzymes.
The end amino group of lysine can be mono-, di- or tri-methylated. Dependent on this meth‐
ylation state, the binding affinity of chromatin-associated proteins varies greatly. Methyla‐
tion of histone 3 lysines 4 and 27 is catalyzed by trithorax and polycomb family of proteins.
H3K27 is di- and trimethylated by enhancer of zeste homolog 2 (EZH2), a polycomb family
protein [67]. The enzyme that reverses H3K27 methylation was not known until the discov‐
ery of two demethylases, ubiquitously transcribed tetratricopeptide repeat, X chromosome
(UTX) and Jumonji domain containing 3 (JMJD3), both of which are members of the Jmje do‐
main-containing protein family [68]. EZH2 has been reported to be mutated and inactivated
in MDS [69], but is also overexpressed in other subsets of MDS [70]. UTX mutations and/or
deletions have also been observed in patients with MDS and chronic myelomonocytic leuke‐
mia [61, 71-73].
3. Histone acetylation status
Acetylation of nucleosomal histones in part regulates gene transcription in most cells. Dif‐
ferential acetylation of nucleosomal histones results in either transcriptional activation (hy‐
peracetylation and an open chromatin configuration) or repression (hypoacetylation and
compacted chromatin) [74, 75]. The role of chromatin remodeling in carcinogenesis was
studied with the help of inhibitors of HDACs (HDIs). HDIs induce the hyperacetylation of
nucleosomal histones in cells resulting in the expression of aberrantly repressed genes (e.g.,
tumor suppressor genes) that produce growth arrest, terminal differentiation, and/or apop‐
tosis in carcinoma cells, depending on the HDI and dose used, and the cell type [76-79]. The
inappropriate recruitment of HDACs provides at least one mechanism by which oncogenes
could alter gene expression in favor of excessive proliferation. Thus, orally active HDIs with
low toxicity towards normal cells and tissues, which would effectively inhibit tumor growth
are needed for epigenetic anticancer therapy. In October 2006, the US Food and Drug Ad‐
ministration (FDA) approved the first drug of this new class, vorinostat (SAHA, Zolinza) for
treatment of cutaneous T-cell lymphoma. Several further HDIs (romidepsin, belinostat, so‐
dium phenylbutyrate, valproic acid, entinostat, and mocetinostat) are in clinical trials. HDIs
have shown significant activity against a variety of hematological and solid tumors at doses
that are well tolerated by patients, both in monotherapy as well as in combination therapy
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with other drugs. Combined DNA methyltransferase and histone deacetylase inhibition are
used in experiments in vitro but also in clinical trials in MDS and AML patients [6, 39].
4. MicroRNAs and epigenetic machinery
MicroRNAs (miRs) belong to a class of small non-coding regulatory RNA that act through
binding to the 3´ -UTR of target mRNA and leading to translational repression or degrada‐
tion of target mRNA at post-transcriptional level. MiRs can directly target epigenetic effec‐
tors such as DNMTs, HDACs and polycomb repressive complexes. On the other hand, some
miRs (miR-9, 34b/c, 124, 127, 137, 145, 146a, 148, -203, let-7a-3, and others) are epigenetically
regulated [80, 81].
MiR-29b targets DNMT3A mRNA [18, 82, 83]. In addition, some isoforms of DNMT3B are
targeted by miR-148 [84]. MiR-26a, 101, 205 and -214 regulates EZH2 [85-90].
Dostalova Merkerova et al. found nine upregulated genes for miRs located at chromosome
14q32 in CD34+ cells separated from mononuclear cells of bone marrow obtained from MDS
patients [91]. 14q32 region contains 40 miR genes with imprinted expression controlled by a
distant differentially methylated region. For example miR-127, a member of the 14q32 re‐
gion, is involved in B-cell differentiation process through posttranscriptional regulation of
BLIMP1, XBP1, and BCL6 genes [91]. BLIMP1 (B lymphocyte induced maturation protein 1)
is a zinc finger transcriptional repressor which functions as a master regulátor of terminal
differentiation of B cells into plasma cells. XBP1 (X-box binding protein 1) is transcription
factor that regulates MHC class II genes by binding to a promoter element referred to as an
X box. BCL6 (B-cell lymphoma 6 protein) is a transcriptional represor which regulates ger‐
minal center B cell differentiation and inflammation.
5. Protein EVI1 and epigenetic machinery
EVI1 (the ecotropic viral integration site 1) is encoded by gene on chromosome 3q26 [92-95].
The oncoprotein EVI1 and the DNMT3 co-operate in bindig and de novo methylation of tar‐
get DNA [96]. EVI1 forms a bridge between the epigenetic machinery and signaling path‐
way [97, 98]. EVI1 represses PTEN (phosphatase and tensin homolog) expression and
activates PI3K/AKT (Protein kinase B)/mTOR via interaction with polycomb proteins [97,
98]. Overexpression of EVI1 predicts poor survival in MDS and AML [99]. MDS patients
with inversion of chromosome 3 and with EVI1 transcriptional activation achieved morpho‐
logical and cytogenetic response to azacitidine [100].
6. Epigenetic therapy in MDS and AML
Treatment with DNMT inhibitors is a rational strategy with the aim to reinduce the expres‐
sion of epigenetically silenced genes for tumor suppressors and other targeted genes, often
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connected with response to chemotherapy. Responses to therapy with DNMT inhibitors are
up to now not fully elucidated. We have no clear evidence for DNMT overexpression in
MDS and the decrease in global methylation after treatment with demethylating agents has
not correlated with disease response. Changes in differentiation and/or apoptosis, and in‐
duction of a immune response can be also involved [28-38, 101].
DNA methylation of upstream regulatory element (URE) plays an important role in downre‐
gulation of transcription of PU.1 gene. PU.1 is the transcription factor and tumor suppressor
necessary for myeloid differentiation. Azacitidine treatment demethylated in vitro URE lead‐
ing to upregulation of PU.1 followed by derepression of its transcriptonal targets and onset of
myeloid differentiation [102]. DNA demethylation and a shift from a repressive histone pro‐
file to a more active profile that includes the reassociation of RNA polymerase II (Pol II) with
the targeted promoters are necessary for tumor suppressor gene reactivation [103].
Even if a complete understanding of the mechanism of action of azanucleotides remains to
be elucidated, their pharmacodynamic effects promote enhanced survival independently of
any ability to eliminate the MDS clone. The MDS clone persists in many patients treated by
DNMT inhibitors but this clone is modulated and hematologic function is improved togeth‐
er with survival of patients.
It has been almost 50 years since the synthesis and antitumor activity of azacitidine (AC)
was described [104, 105]. AC is a pyrimidine nucleoside analog of cytidine and is character‐
ized by a presence of an extra nitrogen atom at position C5 of pyrimidine ring. This modifi‐
cation leads to a blockade of cytosine methylation via a covalent trapping of DNMT. AC is
believed to utilize a dual mechanism of action following its phosphorylation: 1) hypomethy‐
lation of DNA at low doses and 2) cytotoxicity due to the incorporation into RNA and appa‐
rent interaction with protein biosynthesis at high doses. To overcome cytotoxicity, a deoxy
analog of AC, 5-aza-2´-deoxycytidine (decitabine, DAC) was synthesized, which is incorpo‐
rated only into the DNA following its phosphorylation. DAC significantly inhibits DNA
methylation at lower concentrations and with less cytotoxicity in comparison with AC [106].
Both, AC and DAC, possess high cytotoxicity at their maximal tolerated doses and are un‐
stable in aqueous solution.
7. Azacitidine clinical studies
Patients with MDS were randomly treated with either azacitidine or best supportive care in
the CALGB 9221 study [107]. A total of 191 patients with a median age of 68 years were
used. Azacitidine (75 mg/m2/day) was injected subcutaneously in 7-day cycles beginning on
days 1, 29, 57, and 85 (every 28 days). If a beneficial effect was not demonstrated by day 57
and no significant toxicity other than nausea or vomiting had occured, the dose of AC was
increased by 33%. Once benefit occured on a particular dosage, AC was continued unless
toxicity developed. Patients were assessed after the fourth cycle. Those who achieved com‐
plete response (CR) continued on AC until either CR or relapse occured. After 4 months of
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supportive care, any patients with worsening dinase were permitted to cross over to treat‐
ment with AC. Overall, 59% of patients had either refractory anemia with excess blasts
(RAEB) or RAEB in transformation (RAEB-T) according to French-American-British (FAB)-
defined criteria, and 65% of patients were red blood cell transfusion dependent. Sixty per‐
cent of patients in the azacitidine arm (including 7% of patients with CR, 16% with a partial
response /PR/, and 37% with hematologic improvement /HI/), compared with 5% of patients
in the control arm, responded to treatment (p฀0.001). The median time to leukemic transfor‐
mation or death was 21 months in patients treated with AC compared with 12 months in the
best supportive care (p=0.007). The median overall survival was 20 months for AC-treated
patients compared with 14 months for patients assigned to best supportive care. 53% of pa‐
tients on best supportive care received azacitidine after crossover. A further benefit of AC
over supportive care was a significant improvement in quality of life (physical functioning,
fatigue, dyspnea) in patients treated with AC compared with patients in the control arm. AC
did not increase the rate of infection or gastrointestinal bleeding above the rate associated
with underlying disease.
The AZA-001 trial was an international, randomized phase III study designed to test the hy‐
pothesis that AC significantly extends overall survival in patients with MDS compared with
standard care regimens including best supportive care, low-dose cytarabine (ara-C, 20
mg/m2 for 14 days every 28 days for at least 4 cycles), or intensive chemotherapy consisting
of induction with higher dose of ara-C (100-200 mg/m2/day for 7 days plus 3 days of daunor‐
ubicin 45-60 mg/m2/day, idarubicin 9-12 mg/m2/day, or mitoxantrone 8-12 mg/m2/day )
[108]. A total of 358 patients with higher-risk MDS were randomly assigned to either azaciti‐
dine as in CALGB 9221 or to standard of care. Median age of patients was 69 years. After a
median follow-up of 21.1 months, the median survival time was significantly better in azaci‐
tidine patients compared with standard of care options (24.5 versus 15.0 months, respective‐
ly p=0.001) irrespective of age, percentage of marrow blasts or karyotype. In particular,
overall survival was prolonged for azacitidine in patients with -7 / del(7q) cytogenetic ab‐
normality, median overall survival was 13.1 months in the azacitidine group compared with
4.6 months in the standard of care group (p=0.00017). Progression to AML was significantly
delayed in patients treated with AC (17.8 months in the AC group versus 11.5 months in the
standard of care group p฀0.001). Transfusion requirements and rate of infections were also
significantly improved in azacitidine patients.
Continued azacitidine therapy beyond time of first response improves quality of response in
patients with higher-risk myelodysplastic syndromes in 48% of patients [109]. This secon‐
dary analysis of the AZA-001 phase III study evaluated the time to first response and the
potential benefit of continued AC treatment beyond first response in responders. Overal, 91
of 179 patients achieved a response to azacitidine; responding patients received a median of
14 treatment cycles (range, 2-30). Median time to first response was 2 cycles (range, 1-16).
Although 91% of first responses occured by 6 cycles, continued azacitidine improved re‐
sponse in 48% of patients. Best response was achieved by 92% of responders by 12 cycles.
Median time from first response to best response was 3.5 cycles (95% confidence interval
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(CI), 3.0-6.0) in 30 patients who ultimately achieved a complete response, and 3.0 cycles
(95% CI, 1.0-3.0) in 21 patients who achieved a partial response.
French group studied a retrospective cohort of 282 higher-risk MDS treated with azacitidine,
including 32 patients who concomitantly received erythropoiesis stimulating agents (ESA)
for a median of 5.8 months after azacitidine onset [110]. Hematologic improvement was
reached in 44% of the ESA and 29% of the no-ESA patients. Transfusion independence was
achieved in 48% of the ESA and 20% of the no-ESA groups. Median overall survival was
19.6 months in the ESA and 11.9 months in the no-ESA patients.
Platelet doubling after the first azacitidine cycle is a promising independent predictor for re‐
sponse and overall survival in MDS, chronic myelomonocytic leukemia (CMML) and AML
patients in the Dutch azacitidine patients [111].
8. Decitabine clinical studies
Two studies used 3-day, 9-dose regimens requiring inpatient hospitalization and two stud‐
ies used 5-10 day decitabine regimens intended for outpatient administration [23, 25].
The US D-0007 phase III study compared decitabine (15 mg/m2 continuous 3-hour intrave‐
nous infusion every 8 hours for 3 days) with supportive care in 170 patients with a con‐
firmed diagnosisof de novo or secondary MDS. The median age of enrolled patients was 70
years (range, 30-85 years). Most patients (69%) had intermediate (Int)-2- or high- risk disea‐
seas defined by the International Prognostic Scoring System criteria, and were red blood cell
transfusion dependent (71%) [23]. No significant difference was seen in median overall sur‐
vival (OS) between patients treated with decitabine and those receiving supportive care
(14.0 versus 14.9 months, respectively; p=0.636). The median duration of response to decita‐
bine treatment was 10.3 months (range, 4.1-13.9 months). Patients received a median of 3
courses of decitabine treatment (range, 0-9).
EORTC 06011 phase III study compared decitabine given on a 3-day inpatient regimen (15
mg/m2 intravenously over 4 hours three times a day for 3 days, every 6 weeks, for a maxi‐
mum of 8 cycles) with supportive care. A total of 233 patients with primary or secondary
MDS, or CMML defined by FAB classification (median age, 70 years; range, 60 to 90 years)
were enrolled [25]. 53% had poor-risk cytogenetics, and the median MDS duration at ran‐
dom assignment was 3 months. The median OS prolongation with decitabine versus best
supportive care was not statistically significant (median OS, 10.1 versus 8.5 months; p=0.38).
M.D. Anderson Cancer Center ID03-0180 randomized phase II study compared three outpa‐
tient decitabine schedules. In this single-institution study, 95 patients (77 with MDS, and 18
with CMML) were randomized to receive 20 mg/m2/day intravenously for 5 days, 20
mg/m2/day subcutaneously for 5 days, or 10 mg/m2/day intravenously for 10 days. Thus, all
patients received the same 100 mg/m2 total decitabine dose in each treatment cycle. Overall,
32 patients (34%) achieved CR and 69 patients (73%) had an objective response. The 5-day
intravenous schedule, which had the highest dose-intensity, was selected as optimal. The
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CR rate in that arm was 39% compared with 21% in the 5-day subcutaneous arm and 24% in
the 10-day intravenous arm (P<0.05). The high dose-intensity arm (the 5-day intravenous
schedule) was also superior at inducing hypomethylation at day 5 and at activating the ex‐
pression of the cell cycle inhibitor p15INK4B at days 12 or 28 after therapy. The 5-day intrave‐
nous schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.
North American multicenter DACO-020 ADOPT phase II study started on the results of the
study of M.D. Anderson Cancer Center dealing with efficacy and safety of decitabine in the
5-day intravenous schedule, every 4 weeks in 99 patients with MDS (de novo or secondary).
The primary end point was the overall response rate (ORR) by International Working Group
criteria. Secondary end points included cytogenetic responses, hematological improvement,
response duration, survival and safety. The ORR was 32% (17 complete responses plus 15
marrow complete responses and the overall improvement rate was 51%, which included
18% of hematologic improvement. Decitabine can be administered in an outpatient petting
with comparable efficiacy and safety to the US FDA- approved impatient regimen.
9. Comparison of azacitidine and decitabine
Azacitidine and decitabine appear to have similar administration costs. As far as adverse
events azacitidine is well tolerated. Grade 3 and 4 neutropenia was observed for 91% pa‐
tients in the azacitidine treated group, and 76% in the best conventional care group. Grade 3
and 4 thrombocytopenia occurred among 85% of patients in the azacitidine treated group
and 80% in the best conventional care group. Higher risk of febrile neutropenia (23%) was
described in the US D-0007 phase III decitabine study. In this study 87 % of neutropenia and
85% of thrombocytopenia in response to decitabine were reported. In AZA-001 study the
median OS was 24.5 months for azacitidine compared with 15.0 month for the best conven‐
tional care [108]. Decitabine has not demonstrated a survival advantage compared with the
best conventional care (14.0 versus 14.9 months) [23]. In the EORTC 06011 study, the median
OS was 10.1 months for decitabine and 8.5 months for supportive care [25]. Comparing re‐
sults from different studies suggests similar median number of cycles to first response for
azicitidine (2.3 cycles /64 days/ in CALGB 9221 study) and decitabine (2 cycles /3.3 months/
in the D-0007 study and 2 cycles /2 months/ in DACO-020 ADOPT trial) [23, 106]. For azaci‐
tidine treated patients, the median duration of response was 15 months in CALGB 9221
study [107] and 13.6 months in AZA-001 trial [108]. For decitabine treated patients, the me‐
dian duration of response ranged from 8.6 months for EORTC 06011 study [25], 10 months
in the DACO-020 ADOPT trial, to 10.3 months in the D-0007 study [23].
10. Biomarkers of sensitivity to hypomethylating agents
A number of research groups have focused on the identification of methylation patterns
that would predict for response in MDS. No such profile exists. Baseline methylation pat‐
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terns were not associated with response to hypomethylating agents. The significant corre‐
lation was observed between reduced methylation over time and clinical outcome. Further
studies of methylation dynamics both before and after treatment with hypomethylating
agents will be useful to determine the ability of these markers to direct treatment. DNA
methylation of upstream regulatory element (URE) controlling the transcription of PU.1
gene may be a new biomarker for the prediction which patiens will bendit from thera‐
py by hypomethylating agents [102].
Several other biomarkers, such as mutations in TET2 gene and levels of miR-29b have been
reported to be associated with responses to azacitidine and decitabine, respectively. TET2 is
a protein involved in the conversion of 5-methylcytosine to 5-hydroxymethylcytosine and
could therefore result in passive induction of DNA methylation. TET2 mutations were re‐
cently reported to be associated with clinical response to azacitidine but not with survival.
Contradictory results were obtained by another research group [112]. TET2 mutations were
described in 15% of 86 patients. The response rate to AC was 82% in the mutated patients
and 45% in the nonmutated patients with wild TET2 gene. Mutated TET2 (p=0.04) and fa‐
vorable cytogenetic risk (intermediate risk: p=0.04, poor risk: p=0.048 compared with good
risk) independently predicted a higher response rate. TET2 status may be a genetic predictor
of response to AC, independently of karyotype. Expression levels of DNMT1, an enzyme in‐
volved in maintenance of methylation patterns, are regulated by miR-29b. Higher levels of
miR-29b were associated with clinical response to decitabine.
Circulating cell-free DNAs from plasma and serum of patients with MDS can be used to de‐
tect genetic and epigenetic abnormalities. The plasma DNA concentration was found to be
relatively high in patients with higher blast cell counts in bone marrow.
11. Resistance to hypomethylating agents
There is a subgroup of patients with MDS who do not respond to therapy with hypomethy‐
lating agents and a large, growing cohort of patients that lose progress while on azacidine or
decitabine therapy. Since the mechanism of resistance to hypomethylating agents are not
known, selection of therapy is largely empiric but must take into account the age, comorbid‐
ities, and performance status of the patient, as well as the characteristics of the disease at the
time of treatment failure. Higher intensity approaches and allogeneic stem cell transplanta‐
tion can yield improved response rates and long-term disease control but should be limited
to a selected cohort of patients who can tolerate the treatment-related morbidities. For the
majority of patients who likely will be better candidates for lower intensity therapy, several
novel, investigational approaches are becoming available. Among these are newer nucleo‐
side analogues, inhibitors of protein tyrosine kinases, molecules that interact with redox sig‐
naling within the cell, immunotherapy approaches, and others.
In clinical trials, some patients do not respond to hypomethylating agents initially (primary re‐
sistance) and most patients who initially respond to treatment, eventually relapse (secondary
resistance) despite continued therapy with hypomethylating agents. Most primary mecha‐
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nisms of resistance are based on metabolic pathways. The primary resistance is caused by the
insufficient intracellular concentration of nucleoside triphosphates resulting from deoxycyti‐
dine kinase deficiency (DCK mutations or aberrant gene expression), increased deamination
by cytidine deaminase (CDA), or high dNTP pools. Higher ratio of CDA/DCK in a subset of
patients means that decitabine is less activated through mono-phosphorylation by DCK and
more inactivated through deamination by CDA in non-responders. Secondary resistance is
likely due alternate progression pathways as a less aberrant DNA methylation was found dur‐
ing the treatment with hypomethylating agent than at diagnosis, and there were no significant
changes in decitabine metabolism gene expression.
12. New hypomethylating agents
Current hypomethylating agents are limited due to route of administration and potency as
inducers of DNA hypomethylation. An oral compound or an agent with a better pharmaco‐
dynamic profile could improve hypomethylating therapy of MDS patients. Initial results
with an oral formulation of 5-azacytidine have been reported.
2´, 3´, 5´-triacetyl-5-azacytidine demonstrates significant pharmacokinetic improvements in
bioavailability, solubility, and stability over the parent compound 5-azacytidine. In vivo
analyses indicated a lack of general toxicity coupled with significantly improved survival.
Pharmacodynamic analyses confirmed its ability to suppress global methylation in vivo. Es‐
terified nucleoside derivatives may be effective prodrugs for azacitidine and encourages fur‐
ther investigation and possible clinical evaluation.
A new salt derivative, oral decitabine mesylate, is used in ongoing trials. A barrier to effica‐
cious and accessible DNMT1-targeted therapy is cytidine deaminase, an enzyme highly ex‐
pressed in the intestine and liver that rapidly metabolizes decitabine int into inactive uridine
counterparts, severely limiting exposure time and oral bioavailability. Oral administration
of 3,4,5,6-tetrahydrouridine (THU), a competitive inhibitor of cytidine deaminase, before or‐
al decitabine extended decitabine absorption time in mice and nonhuman primates and wid‐
ened the concentration-time profile. Therefore, the exposure time for S-phase-specific
depletion of DNMT1 is increased without the high peak of decitabine levels that can cause
DNA damage and cytotoxicity. On the other hand, decreased DNA methylation in inter‐
mediate and high risk AML patients with DNMT3A mutation was linked with higher re‐
lapse rates and an inferior overall survival [113].
5,6-dihydro-5-azacytidine (DHAC) and 2´-deoxy-5,6-dihydro-5-azacytidine (DHDAC) are
hydrolytically stable. There is no evidence of significant genotoxicity and/or mitochondrial
toxicity on mammalian cells. Both compounds are a less toxic alternative of azacitidine and
decitabine and may also be of therapeutic interest.
Another compounds actively being studied in clinical trials are SGI-110 and CP-4200, a sec‐
ond generation hypomethylating agents [38]. One of the limitations of the nucleoside ana‐
logues in the clinical trials has been the side effects, such as thrombocytopenia and
neutropenia, which are probably caused by cytotoxic effects associated with the drug´s in‐
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corporation into the DNA or RNA independently of their DNA hypomethylation value.
This has encouraged the search for inhibitors of DNA methylation that are not incorporated
into DNA or RNA.
Zebularine is a cytidine deaminase inhibitor that also displays antitumor and DNA demethy‐
lating properties. Zebularine is a cytidine analog that contains a 2-(1H)-pyrimidinone ring.
The drug procainamide, approved by the FDA for the treatment of cardiac arrythmias, and
procaine, a drug approved by the FDA for use as a local anesthetic, were proposed as non-
nucleoside inhibitors of DNA methylation. This action is thought to be mediated by their
binding to GC-rich DNA sequences. Both, procaine and procainamide, are derivatives of 4-
amino-benzoic acid.
Dietary phytochemicals, tea catechins, polyphenols, particularly (-)-epigallocatechin-3-gal‐
late decreased the levels of 5-methylcytosine, DNMTs activity, mRNA and protein levels of
DNMT1, DNMT3A and DNMT3B and also decreased histone deacetylase aktivity and
stimulated re-expression of the mRNA and proteins of silenced tumor suppressor genes.
N-phthalyl-L-tryptophan  (RG108)  and  its  dicyclo-hexyl-amine  salt  effectively  blocked
DNA  methyltransferases  in  vitro  and  did  not  cause  covalent  enzyme  tramping  in  hu‐
man cell  line.  Incubation of cells  with RG108 resulted in signifiant demethylation of ge‐
nomic DNA without any detectable toxicity. RG108 caused demethylation and reactivation
of  tumor  suppressor  genes.
13. Combinations of hypomethylating agents with histone deacetylase
inhibitors or other drugs
In vitro, most of histone deacetylase inhibitors (HDACI) have been shown to have synergis‐
tic activity when combined with either azacitidine or decitabine. Therefore, phase I and II
clinical trials were performed. Combination of decitabine and valproic acid was safe and ac‐
tive and time to response was accelerated [6,12]. A randomized phase II trial has been con‐
ducted at M.D. Anderson Cancer Center comparing decitabine versus decitabine in
combination with valproic acid [6, 12, 39]. Results did not show any significant benefit with
the combination of decitabine and valproic acid. Similar results were obtained with combi‐
nation of azacitidine and MS-275 (Entinostat), a potent HDACI [12, 39].
Phase I trial for combination of lenalidomide with azacitidine has shown this combination to
be very safe and clinically active in MDS [114]. In this study 18 patients ( 2 intermediate 1-,
10 intermediate 2- and 6 high- risk) were enrolled with median age 68 years (range, 52 to 78
years). Interval from diagnosis was 5 weeks (range, 2 to 106 weeks) and follow-up was 7
months (range, 1 to 26 months). Azacitidine (75 mg/m2/day) on days 1 through 5 and lenali‐
domide (10 mg) on days 1 through 21 were used. The combination of lenalidomide and aza‐
citidine is well tolerated with encouraging clinical activity.
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14. Lenalidomide with potent immunomodulatory, antiangiogenic and
direct neoplastic cell inhibitory activity
Interstitial deletions involving long arm of chromosome 5 are one of the common cytogenet‐
ic abnormalities in MDS patients [115-117]. MDS with isolated del(5q) in which the sole cy‐
togenetic abnormality is del(5q) is a distinct entity with a risk of evolution into AML of
approximately 10%. It is characterized by macrocytic anemia with or without other cytope‐
nias and/or thrombocytosis. Myeloblasts comprise less than 5% of bone marrow and less
than 1% of peripheral blood.
Lenalidomide [3-(4-amino-1-oxo1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione] is 4-ami‐
no-glutarimide analog of thalidomide with potent immunomodulatory, antiangiogenic and
direct neoplastic cell inhibitory activity [118-120]. Thalidomide was synthesized in Germa‐
ny, in 1954, from α-phtaloylisoglutamine, to be used as sedative and antimetic drug. In 1957,
after a short period of preclinical studies, thalidomide was approved for first trimester ges‐
tational sickness in humans. The appearance of malformations such as phocomelia in the
newborn banned its use three years later. The US Food and Drug Administration (FDA) ap‐
proved thalidomide in 1998 for the treatment of erythema nodosum leprosum. A small but
consistent fraction of transfusion-dependent MDS patients achieved transfusion independ‐
ence by treatment with thalidomide.
Lenalidomide was developed in order to avoid thalidomide side effects (sedation and neu‐
ropathy), and to increase efficacy [118-120]. Lenalidomide shares a number of structural and
biological properties with thalidomide but is safer and more potent than thalidomide. Lena‐
lidomide was first studied in a single- center trial [121]. Erythroid and cytogenetic responses
were achieved in a study of 43 patients with MDS, particularly in patients with isolated
del(5q31-33) [28]. Lenalidomide was administered in three different dosing schedules: 25 mg
daily, 10 mg daily, and 10 mg daily for 21 days of each 28-day cycle [121]. The erythroid re‐
sponse rates were highest in patients with the International Prognostic scoring system (IPSS)
low or intermediate 1 risk MDS. Transfusion independence was achieved in 20 of 32 patients
(63%), and three additional patients had reduced red blood cells transfusion needs [121].
Ten of 12 patients (83%) with del(5q31) experienced major erythroid responses, defined as
sustained transfusion independence, compared with a 57% response rate in patients with a
normal karyotype and a 12% response rate in patients with other cytogenetic abnormalities.
Complete cytogenetic remissions were achieved in 75% of the del(5q31) patients (9 of 12 of
these patients), with one additional patient achieving at least a 50% decreases in abnormal
metaphases [121]. Myelosuppression (neutropenia and/or thrombocytopenia) was the most
common adverse event, but it was dose-dependent, favoring the 10 mg daily dose for 21
days of each 28-day cycle.
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15. Multicenter phase II trials of lenalidomide
After encouraging results of a single-center trial (MDS-001) [28], the effect of lenalidomide
on the 5q31 deletion MDS syndrome was investigated in a large multicenter phase II study
(MDS-003) and led to its FDA approval for red blood cell transfusion-dependent anemia due
to low or intermediate-1 risk MDS associated with a chromosome 5q deletion with or with‐
out additional cytogenetic abnormalities [122]. The initial schedule was 10 mg of lenalido‐
mide for 21 days every 4 weeks, but the treatment schedule was subsequently amended so
that the 10 mg dose was given every day because of the shorter interval between initiation
of treatment and a response in the pilot study. Of the 148 transfusion-dependent patients
who were included in the study, 46 were treated on the 21-day schedule and 102 received
continuous daily dosing. Overall, 112 (76%) patients responded to treatment with a median
time to response 4.6 weeks. Among these, 99 no longer needed transfusions by week 24,
while the remaining 13 patients had a reduction of 50% or greater in the number of transfu‐
sions required. There was no significant difference in response rate between the two treat‐
ment schedules. Response rate was independent of additional chromosomal aberrations.
Patients with pretreatment thrombocytopenia had an inferior outcome. Almost half of the
patients, including some with complex karyotypes, had a complete cytogenetic response.
Neutropenia and thrombocytopenia were the most common treatment-associated adverse
events. Most other adverse events were of low or moderate severity and included pruritus,
rash, diarrhea, and fatigue. Adjustment of the lenalidomide dose due to intolerance was re‐
quired in 124 patients, including 93 of those receiving continuous daily dosing and 31 of
those receiving 21-day dosing. Thirty patients discontinued lenalidomide treatment because
of adverse events including thrombocytopenia or neutropenia, rash AML, anemia, facial
edema, congestive heart failure, urticaria, diarrhea, weight loss, renal insufficiency, cerebro‐
vascular accident, dementia, dyspnea, pyrexia, and pneumonia.
However, the European Medicine Agency (EMEA) did not approve lenalidomide for this in‐
dication, raising the concern, based on the results of the MDS-003 trial, that lenalidomide
may trigger progression to AML in some patients with del(5q).
Current recommendation state that treatment with lenalidomide in del(5q) MDS should be
continued until disease progression [123]. The question whether interrruption of lenalido‐
mide treatment for patients in remission would be beneficial has been also addressed [124].
It is important for several reasons: 1) it could reduce costs and side effects; 2) it could facili‐
tate disease progression to AML. Different mechanisms have been discussed to explain
AML progression. Evidence that pre-therapeutic telomere length was significantly shorter in
those patients who ultimately transformed to AML than in those who did not was presented
[125]. Transformation to AML is occasionally observed, paticularly in patients without a cy‐
togenetic response to lenalidomide. Jädersten et al. [126] performed molecular studies in a
patient with classical 5q- syndrome with complete erythroid and partial cytogenetic re‐
sponse to lenalidomide, who evolved to high-risk MDS with complex karyotype. Immuno‐
histochemistry of pretreatment marrow biopsies revealed a small fraction of progenitors
with overexpression of p53 and sequencing confirmed a TP53 mutation. TP53 mutated sub‐
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clones have not previously been detected in 5q- syndrome and indicates heterogeneity of
this disease. Subsequently, TP53 mutations with a median clone size of 11% (range, 1% to
54%) were detected in 10 from 55 (18%) low-risk MDS or intermediate-1 risk patients with
del(5q) by next-generation sequencing [127]. TP53 mutations are associated with strong nu‐
clear p53 protein expression. Patients with mutation had significantly worse outcome. TP53
mutations may lead to genetic instability and disease progression. This clonal heterogeneity
in low-risk MDS patients with del(5q) may be of importance when assessing the prognosis
and selecting the therapy in these patients. It has been speculated that continuous adminis‐
tration of lenalidomide may lead to selective pressure on stem cells that induces genomic
instability, resulting in acute leukemia transformation [128].
Longest transfusion-free intervals are achieved in patients low-risk MDS patients with
del(5q) who are exposed to lenalidomide 6 months beyond complete cytogenetic remission
[41, 124]. Lenalidomide should not be withdrawn prematurely in patients who achieve
transfusion independence as partial cytogenetic remission patients seem to have a higher re‐
lapse rate than complete cytogenetic remission patients.
Treatment  by  lenalidomide  is  based  on  scientific  knowledge  because  small  deletions  in
several  ribosomal  genes,  including  RPS14,  were  found  in  CD34+  cells  not  only  in  pa‐
tients with del(5q) but also in patients with non-del(5q) MDS [41,  42,  129-131].  This ob‐
servation suggested that deregulated ribosomal biogenesis may not be limited to del(5q)
MDS. Czibere et  al.  [132]  showed that  lower risk non-del(5q) MDS patients with RPS14
haploinsufficiency  tend  to  have  prolonged  survival.  Defective  ribosomal  biogenesis  has
a  lead  role  in  disrupting  erythropoiesis  in  a  variety  of  anemias.  Disruption  of  riboso‐
mal biogenesis has been clearly demonstrated in multiple ribosomopathies to greatly per‐
turb  p53  signaling  [130,  131].
Bone marrow aspirates of patients who responded to lenalidomide showed before treatment
decreased expression of the set of the genes needed for erythroid differentiation. Lenalido‐
mide seems to overcome differentiation block in del(5q) patients with decreased expression
of these genes compared to the non-responders [131]. Thus, lenalidomide restored erythroid
differentiation potential by upregulation of the suppressed erythroid gene signature (genes
for α- and β-globin, ankyrin 1, band 3, band 4.2, carbonic anhydrase, ferrochelatase and gly‐
cophorin B) [133].
The  “Groupe  Francophone  des  Myélodysplasies”  conducted  a  multicenter  phase  2  trial
with  lenalidomide  in  intermediate-2  (19  patients)  and high-risk  MDS (28  patients)  with
del(5q).  Forty  seven patients  (24  males  and 23  females,  with a  median age of  69  years,
range,  36-84 years)  were treated.  Forty three  patients  of  47  patients  had transfusion-de‐
pendent anemia. Patients received 10 mg lenalidomide once daily orally during 21 days
every  4  weeks.  In  patients  without  response  after  8  weeks,  the  lenalidomide  dose  was
increased to  15  mg/day in  the  same time schedule  during an additional  8  weeks.  If  no
response  was  found  in  this  additional  time  of  treatment,  lenalidomide  was  discontin‐
ued. Thirteen of the 47 patients (27%) achieved response according to International Work‐
ing  Group  (IWG)  2006  criteria.  Median  duration  of  overall  response  was  6.5  months,
11.5 months in patients who achieved the complete remission. Grade 3 and 4 neutrope‐
nia  and  thrombocytopenia  were  seen  in  most  patients.
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Möllgård et al. [7] hypothesized that increasing doses of lenalidomide may be successfully
used in high-risk MDS and AML with chromosome 5 abnormalities. They tested this hy‐
pothesis in prospective phase II multicenter trial with 28 patients (12 with intermediate-risk
2 or high-risk MDS and 16 with AML). Oral lenalidomide was given at a dose of 10 mg/day
in weeks 1 to 5. The dose was increased to 20 mg/day in weeks 6 to 9, and to 30 mg/day in
weeks 10 to 16. In the case of suspected drug-related toxicity the dose was lowered to 5 mg/
day. The overall response rate in treated patients with MDS was 36% (4/11) and that for
AML patients was 20% (3/15). Seven patients stopped therapy due to progressive disease
and nine because of complications, most of which were disease-related. Patients with TP53
mutations responded less well than those without mutations. No responses were observed
among 11 cases with deleterious TP53 mutation [7].
16. Randomized phase III placebo-controlled study of lenalidomide in
del(5q) patients
This study [134] examined the safety of lenalidomide in a randomized phase III trial
(MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality.
The similar criteria as in the MDS-003 study were chosen. Two hundred five patients were
randomized to receive treatment with either lenalidomide 10 mg orally daily for 21 days of
each 28-day cycle, lenalidomide 5 mg orally daily for 28 days of each 28-day cycle, or place‐
bo. Erythroid responses were assessed at 16 weeks. Nonresponders were then in open-label
treatment and they were excluded from the efficacy analysis. Red blood cell transfusion in‐
dependence was achieved in 53.6% of patients treated on 10 mg arm, 33.3% on 5 mg arm
and 6% on the placebo arm. Cytogenetic response rates were also highest in the 10 mg arm
(41.5% of patients), while in 5 mg arm (17.4%) and in the placebo arm (0%). The median rise
in hemoglobin at the time of the best response was also higher in patients treated with the
10 mg lenalidomide. No difference in the rate of AML trandsformation among three arms
was found. This study confirmed that the preferred starting dose of lenalidomide in patients
with del(5q) low-/int-1-risk MDS remains 10 mg.
17. Further clinical studies of lower risk MDS patients with del(5q)
treated with lenalidomide
Many of the initial clinical and laboratory observations obtained in the MDS-003 trial were
confirmed in the study of Le Bras et al. [135]. Ninety five lower risk MDS patients (low and
intermediate 1 risk in IPSS, 25 males and 70 females with a median age of 70.4 years) with
del(5q) were treated with 10 mg of lenalidomide daily, 21 days every 28 days for at least 16
weeks. Patients with at least a minor erythroid response after 16 weeks were treated in the
same way until disease progression, treatment failure or treatment-limiting toxicity.
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Erythroid response was evaluated according to international working group (IWG) 2000 cri‐
teria. Sixty two of the 95 patients (65%) achieved erythroid response according to IWG 2006
criteria. In these 62 patients, 60 patients (63% from 95 patients) achieved red blood cell trans‐
fusion independence. Median time to transfusion independence was 16 weeks (range 8-33
weeks). Fifteen patients who achieved transfusion independence were analyzed for cytoge‐
netic response (20% of complete and 40% of partial cytogenetic response). The rest of these
15 patients (40%) had no cytogenetic response. Six (6.3%) patients progressed to AML and
15 patients died, including 6 patients who had achieved transfusion independence. In the
MDS-003 trial, the primary endpoint was hematological response, while in the study of Le
Bras et al. transfusion independence. The cytogenetic remission rate was higher in the
MDS-003 trial (73% versus 60% in the study of Le Bras et al. [135]. Neutropenia and throm‐
bocytopenia were the most common adverse events in both studies.
A Japanese multiinstitutional study MDS-007 in MDS patients with del(5q) treated with le‐
nalidomide has been recently performed. This study was targeted on morphologic analysis
and evaluation of the relationship among erythroid response, change of morphologic find‐
ings and cytogenetic response. MDS-007 trial was a single-arm, open-label study. Eleven pa‐
tients were enrolled in this study, including 5 patients with transfusion-dependent anemia
and 6 patients with transfusion-independent symptomatic anemia. Nine patients showed
less than 25% of bone marrow erythroblasts before therapy with lenalidomide and no pa‐
tient had more than 40% of bone marrow erythroblasts at that time. Eight patients showed a
rapid increase of bone marrow erythroblasts to more than 40% on day 85. All patients except
one achieved a major erythroid response as defined by either transfusion independence or
by rapid increase of hemoglobin level in most patients on day 169 of lenalidomide therapy.
One patient without any hematologic response by day 169, achieved a major erythroid re‐
sponse on day 218. Erythroid response could be achieved even without a cytogenetic re‐
sponse. No patient in this analysis showed a hematological relapse prior to cytogenetic one.
These findings suggested that lenalidomide can improve anemia by more than one mecha‐
nism of action and also through mechanism different from del(5q) elimination.
18. Therapy with lenalidomide in combination with another drug in
MDS
In order to maximize the potential benefit from lenalidomide therapy combination strategies
were developed. Lenalidomide in attemp to improve outcome of patients can be combined
with erythropoiesis-stimulating agents (ESA), such as erythropoietin or darbepoietin alpha.
This therapy is based on preclinical observations shoving that lenalidomide significantly po‐
tentiated erythropoietin receptor signaling. The addition of erythropoietin (40, 000 U/week)
for an additional 8-week course had the beneficial effect in low and intermediate-1 risk MDS
patients who had failed prior treatment with lenalidomide monotherapy for 16 weeks. To
evaluate the potential benefit of the combination of lenalidomide and ESA, Park et al. [136]
tried the association in three del5q MDS patients, who were resistant or partially responding
to lenalidomide alone. Lenalidomide had two different actions, one on the disapperance of
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the 5q- clone and the other one on the stimulation of the erythroid production in combina‐
tion with ESA.
In low to intermediate-1 risk non-del(5q) MDS, lenalidomide treatment is less effective with
a lower response rate (25%) and shorter response duration than in the same risk MDS with
del(5q) [41]. Combination of lenalidomide with another drug could improve outcome of pa‐
tients with low to intermediate-1 risk non-del(5q) MDS. Ezatiostat hydrochloride (Telintra,
TLK199), a tripeptide glutathione analog is a reversible inhibitor of the enzyme glutathione
S-transferase P1-1 (GSTP1-1) inhibitor. This inhibitor was developed for the treatment of cy‐
topenias associated with lower risk MDS. Ezatiostat activates jun-N-terminal kinase (JNK),
promoting the growth and maturation of hematopoietic progenitors, while inducing apopto‐
sis in human leukemia blasts. The ability of ezatiostat to activate the caspase-dependent
pathway may help eliminate or inhibit the emergence of malignant clones. Alternatively,
ezatiostat increases reactive oxygen species in dysplastic cells and contibutes by this effect
also to apoptotic death. Based on these mechanisms of action, response rates, non-overlap‐
ping toxicities, and tolerability observed in a single agent ezatiostat phase 1 and 2 studies in
MDS, a study of the combination of ezatiostat and lenalidomide was conducted to deter‐
mine the safety and efficacy of ezatiostat with lenalidomide in non-del(5q) low to intermedi‐
ate-1 risk MDS. Eighteen patients (median age 73 years; range 57-82; 72% male) were
enrolled in the study. Thirteen patients (72%) were intermediate-1 risk and 5 patients (28%)
were low risk. Four patients had abnormal cytogenetics. Twelve patients (67%) were red
blood cell transfusion-dependent and 2 patients (11%) were were platelet transfusion-de‐
pendent. Three of 8 (38%) patients achieved transfusion independence including 1 respond‐
er who did not respond to prior lenalidomide. Ezatiostat caused clinically significant
reduction in red blood cell and platelet transfusions. Since ezatiostat is non-myelosuppres‐
sive, it is a good candidate for combination with lenalidomide. The recommended doses of
this combination regimen for future studies is the ezatiostat.
Lenalidomide and azacitidine combination has been already described [14, 114].
Romiplostim (AMG 531, Nplate) is an Fc-peptide fusion protein (peptibody) that acts as a
thrombopoietin receptor agonist. It has no amino acid sequence homology with endogenous
thrombopoietin. Romiplostim stimulates megakaryopoiesis and thrombopoiesis by binding
to and activating the thrombopoietin receptor and downstream signaling. Romiplostim ap‐
peared well tolerated in patients with lower risk MDS and thrombocytopenia. Low platelet
counts in patients with MDS may be due to the underlying disease or due to treatment with
disease-modifying agents, and platelet transfusions are often the only treatment for clinical‐
ly significant thrombocytopenia or bleeding. Randomized phase II study evaluating the effi‐
cacy and safety of romiplostim treatment of patients with low or intermediate-1 risk MDS
receiving lenalidomide was performed. This was double-blind, placebo controlled, dose
finding study that evaluated the effect of romiplostim on the incidence of clinically signifi‐
cant thrombocytopenia events (grade 3 or 4 thrombocytopenia and/or receipt of platelet
transfusions) and the safety of romiplostim in patients with low or intermediate-1 risk MDS
receiving lenalidomide. Thirty nine patients (median age 74 years; range, 39 to 90) were
randomized into treatment groups receiving placebo, 500 μg romiplostim, or 750 μg romi‐
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plostim by weekly subcutaneous injections in combination with lenalidomide (one 10 mg
capsule by mouth daily for each 28-day cycle). Fifteen patients (39%) had platelet
counts฀50x109/L and 7 (18%) had del(5q). Treatment continued for a total of four cycles.
Twelve patients (31%) discontinued the study. Disease progression to AML was reported in
1 patient in the romiplostim 500 μg group. Response was 8% for the placebo, 36% for 500 μg
romiplostim, and 15% for 750 μg romiplostim groups. Romiplostim appeared to be well toll‐
erated in low or intermediate-1 risk MDS patients receiving lenalidomide.
It is possible that effect of lenalidomide could be augmented with the addition of anoth‐
er immunomodulation agent, cyclosporine A. A single-arm, open-label study of the effica‐
cy and safety of lenalidomide in combination with cyclosporine A in red blood cell
transfusion-dependent both 5q- and non 5q- MDS patients started at Weill Cornell Med‐
ical College in New York.
Other drugs are tried and will be probably used in combinations with lenalidomide in the
treatment MDS patients with del(5q) in the future. Dexamethasone and lenalidomide rescue
erythropoiesis, alone and in combination, in RPS14- and RPS19- (ribosomal proteins of small
ribosomal subunit) deficient cells [137]. L-leucine was also studied in RPS14- and RPS19- de‐
ficient cells [138-141]. The combined use of L-leucine and lenalidomide might be considered
for therapy in MDS patients with the del(5q) since there is evidence to suggest that these
two drugs act through different mechanism and their effect may be synergistic.
19. Mechanisms of action of lenalidomide
Lenalidomide shares a number of structural and biological properties with thalidomide
but is safer and more potent than thalidomide. Both drugs appear to function through
four mechanisms: immunomodulatory, anti-inflammatory, anti-angiogenic and direct neo‐
plastic cells inhibitory [41, 42, 142]. Lenalidomide has a direct erythropoiesis stimulating
effect. Wei et al. [143] demonstrated that the haplodeficient enzymatic targets of lenalido‐
mide within the commonly deleted region are two dual-specificity phosphatases, the cell
division cycle 25C (Cdc25C) and the protein phosphatase 2A (PP2A). These phosphatas‐
es are coregulators of G2-M checkpoint in the cell cycle and thus, their inhibition by lena‐
lidomide leads to G2 arrest and apoptosis of del(5q) specimens. The mechanism of action
is different in non-del(5q), where lenalidomide restores and promotes effective erythropoi‐
esis with no direct cytotoxic effect [144]. Lenalidomide promotes erythropoiesis and fe‐
tal hemoglobin production in human CD34+ cells [144]. The increased fetal hemoglobin
expression was associated with epigenetic effect on chromatin (an increase in histone 3 ace‐
tylation on the γ-globin gene promoter).
The similar epigenetic modulation of gene for p21(CIP1/WAF1) by lenalidomide was descri‐
bed in both lymphoma and multiple myeloma. A potent cyclin-dependent kinase inhibitor
p21(CIP1/WAF1) decreases activity of cyclinE-CDK2 or cyclinD-CDK4/6 complexes, and
thus functions as a regulator of cell cycle progression. The p21 protein can mediate cellular
senescence and also interact with proliferating cell nuclear antigen (PCNA), a DNA poly‐
Leukemia176
merase accessory factor, and plays a regulatory role in S phase DNA replication and DNA
damage repair.
Most MDS patients including those with del(5q) become refractory to erythropoietin (EPO).
EPO is an essential glycoprotein that facilitates red blood cell maturation from erythroid
progenitors and mediates erythropoiesis. EPO acts through EPO-receptor (EPO-R) and the
signal transducer and activator of transcription 5 (STAT5). Disruption of STAT5 results in a
variety of cell-specific effects, one of which is the impaired erythropoiesis. Lenalidomide re‐
lieves repression of ligand-dependent activation of the EPO-R/STAT5 pathway. Ebert et al.
[133] showed that target genes of this pathway are underexpressed in lenalidomide-respon‐
sive MDS patients wihout del (5q). Lenalidomide promotes erythropoiesis in MDS by CD45
protein tyrosine phosphatase inhibition. CD45 phosphatase is overactivated in MDS and
may inhibit phosphorylation of STAt5 stimulated by EPO-R. Lenalidomide is able to restore
EPO-R/STAT5 signaling that is essential for hematopoiesis. Lenalidomide restores and pro‐
motes effective erythropoiesis in non-del(5q) without direct cytotoxic effect.
A deregulated immune system plays the important role in pathogenesis of MDS. Deregula‐
tion is caused by the alteration of cytokines in the bone marrow microenvironment, deffec‐
tive T-cell regulation and diminished natural killer (NK) cell activity. Deficiences in T cells,
NK cells and interferon-γ (IFN-γ) production were described in the bone marrow and pe‐
ripheral blood of MDS patients. Lenalidomide exhibits potent T-cell costimulatory proper‐
ties and augmented production of IL-2 and IFN-γ [118]. Akt (proteinase B) signaling
pathway and transcription factor AP1 (activator protein 1) are involved in T-cell activation.
Increased numbers and activation of NK and NK T-cell populations were also observed in
peripheral blood cells cultured with lenalidomide.
Anti-inflammatory effects of lenalidomide is based on the inhibition of proinflammatory cy‐
tokines and chemokines, such as TNF-α, IL-1β, IL-6, IL-12, monocyte chemotactic protein-1
and macrophage inflammatory protein-1α. On the other hand, lenalidomide elevates anti-
inflammatory cytokine IL-10. Interestingly, haploinsuficiency of miR-145 and miR-146a in
5q - syndrome increases IL-6 levels by elevation of interleukin-1 receptor-associated kinase 1
(IRAK1), Toll-interleukin-1 receptor domain-containing adaptor protein (TIRAP), tumor ne‐
crosis factor receptor-associated factor-6 (TRAF6), and NF-κB [145].
Angiogenesis, the formation of new blood vessels, plays an important role in the growth
and progression of MDS. Anti-angiogenic effects of lenalidomide are independent of immu‐
nomodulatory effects and are mediated through endothelial cell migration inhibition. The
mechanism by which lenalidomide inhibited vascular endothelial growth factor (VEGF)-in‐
duced endothelial cell migration may be related to VEGF-induced inhibition of Akt phos‐
phorylation. Furthermore, loss of anti-angiogenic effect of lenalidomide predicted disease
progression and an increased risk of transformation to AML.
Lenalidomide does not affect DNA synthesis but inhibits cytokinesis of MDS cells. Cytoki‐
nesis occurs as the final stage of cell division after mitosis. A contractile ring, made of non-
muscle myosin and actin filaments assembles in the middle of the cell adjacent to the cell
membrane. Formins are Rho-GTPase effector proteins that are involved in the polymeriza‐
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tion of actin and effects microtubule during meiosis, mitosis, the maintenance of cell polari‐
ty, vesicular trafficking and signaling to the nucleus. Diaphanous (mDia)-related formin
mDia1 is encoded by DIAPH1 located on the long arm of chromosome 5 (5q31.3) and lies
between the two commonly deleted regions in MDS patients with 5q- syndrome. It is not
clear whether mDia1 plays a role in lenalidomide effect on cytokinesis. Knock-out of DI‐
APH1 in mice has T cell responses and myelodysplastic phenotype.
The clinical effect of lenalidomide is associated with significant increases in the numbers of
erythroid, myeloid and megakaryocytic colony-forming cells and a substantial improvement
in the hematopoiesis-supporting capacity of bone marrow stroma. Lenalidomide induces
significant alterations in the adhesion profile of hematopoietic progenitor cells, including
over-expression of membrane ligands (CXCR4/CD184, CD54/ICAM1, CD11a and CD49d
where CD is cluster of differentiation) and overproduction of soluble stromal cell-derived
factor-1 (SDF-1) and of ICAM1 in the bone marrow microenvironment. CXCR4 is C-X-C che‐
mokine receptor type 4 also known as fusin or CD184. ICAM1 (intracellular adhesion mole‐
cule 1 also known as CD54) is a cell surface glycoprotein. All these effects favor the
maintenance of CD34+ cells in the bone marrow. Lenalidomide-mediated induction of the
SLAM antigen CD48 on patients´ CD34+ cells may be associated with the drug´s apoptosis-
inducing effect through co-stimulatory interactions between CD34+ cells and cytotoxic lym‐
phocytes in the bone marrow microenvironment.
20. Conclusion and perspectives
Despite the encouraging results with azacitidine and decitabine, it is obvious that it will be
important to have access to second generation agents with the capacity to increase faster ear‐
ly response rates with acceptable toxicity profiles. Preliminary results with oral formulation
of both azacitine and decitabine are promising and these forms could improve hypomethy‐
lating therapy of MDS patients in future. Another approach is to develop combination strat‐
egies using either azacitidine or decitabine. Several such approaches are currently studied
and many are promising but not yet fully understood. Including of cytidine deaminase in‐
hibitor in these combinations appears to be important for better results but it needs new
clinical studies. Lenalidomide is currently the treatment of choice for lower risk transfusion-
dependent del(5q) MDS patients, and remains a treatment alternative for the management
of anemia in lower risk MDS without 5q deletion MDS patients with adequate neutrophil
and platelet counts [41, 42]. Lenalidomide has also activity in higher risk MDS and AML
with del(5q) and even in non(del5q) MDS.
Though the mechanism of lenalidomide action has not been definitively determined, it is clear
that there is difference between mechanisms in MDS with del(5q) and MDS with non-del(5q).
In MDS with del(5q), lenalidomide acts through inhibition of phosphatase activity in the
commonly deleted region of the long arm of chromosome 5. This phosphatases play a key
role in in cell cycle regulation. The inhibition of these phosphatases by lenalidomide leads to
G2 arrest, followed by apoptosis of del(5q) specimens. The direct cytotoxic effects of lenali‐
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domide on the del(5q) clone are also very important. Lenalidomide inhibits the malignant
clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-
syndrome patients. However, SPARC is dispensable for murine hematopoiesis [146]. While
haploinsufficiency of the RPS14 gene appears to be a key contributor to erythropoietic fail‐
ure associated with del(5q) MDS, the critical genes responsible for clonal dominance in
del(5q) high-risk MDS and AML are less well-defined. It is known that this deleted region is
different in del(5q) high-risk MDS and AML [147]. The effect of lenalidomide in these cases
needs to identify further biologic features accounting for response, thereby allowing rational
use of this drug, both alone and in combination with another agents.
In MDS with non-del(5q), an increased expression of adhesion molecules caused by lenalido‐
mide treatment leads to recovery and maintenance of the CD34+ cells through interactions be‐
tween the hematopoietic and stromal cells. This effect of lenalidomide on the bone marrow
microenvironment causes abrogation of the function of pro-apoptotic and pro-inflammatory
cytokines. Lenalidomide is capable to increase red blood cell production independently of ri‐
bosome dysfunction. Lenalidomide restores and promotes effective erythropoiesis without di‐
rect cytotoxic effect. Lenalidomide activates the EPO-R/STAT5 pathway.
New cytogenetic tools such as fluorescence in situ hybridization (FISH) or single nucleotide
polymorphism array (SNP-A)-based karyotyping increased the diagnostic yield over meta‐
phase cytogenetics. Sugimoto et al. [148] have recently found with help of these new cytoge‐
netic tools that normal karyotype and gain of chromosome 8 were predictive of response to
lenalidomide in non-del(5q) patients with myeloid malignancies.
The presence of multiple cellular and genetic abnormalities in MDS and AML is common
and suggests that combination therapy targeting different mechanisms of action may be
beneficial particularly in higher-risk MDS disease, for which both microenvironment and
cell regulatory mechanisms play a role. The optimal dose, schedule and duration of treat‐
ment is still an area of active investigation, especially in the use of lenalidomide combina‐
tions with other drugs.
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